Biotech IPOs Return as Regional Hubs Grow Amid FDA Regulatory Uncertainty
Four biotech companies went public in one week raising nearly $1 billion, signaling a potential thaw in IPO markets after years of quiet activity. Regional life sciences hubs outside Boston and San Francisco are attracting record venture funding, while regulatory uncertainty at FDA continues to concern industry leaders.
After several quiet years for IPOs, four drugmakers—Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics—went public in the same week, raising close to $1 billion combined. The surge might be an important signal that investors may be reopening the IPO window after a period when many biotechs avoided going public altogether.
The return of public market activity comes as regional life sciences hubs outside the traditional centers of Boston and San Francisco continue to expand. North Carolina marked a banner fundraising year in 2025, with venture funding in the life sciences sector hitting a record $1.6 billion, according to data tracked by the North Carolina Biotechnology Center. This easily tops the state's previous high of $1 billion in 2021.
A few select regions of the U.S. are staking their own claims as life sciences hubs, according to the 2025 Global Life Sciences Atlas from CBRE. These include San Diego, New York City, and Raleigh-Durham. Promising early-stage companies can set up shop, join the ecosystem in their local life sciences community, and attract investment dollars from across the globe.
Ten63 Therapeutics, which uses its AI and computational drug discovery platform to develop sought-after therapeutics for certain types of cancer, attracted $15.9 million in Series A financing in 2023 led by a Triangle venture capital firm, Hatteras Venture Partners, which recruited San Francisco VC firm Yosemite as co-lead. The company recently added strategic investment from new investors Chugai Venture Fund and the Gates Foundation, bringing its total funding to over $45 million. In 2023, the company announced a multi-target drug discovery collaboration with Boehringer Ingelheim to enable the discovery of novel therapeutic molecules.
Despite positive investment signals, regulatory concerns persist. In a Q1 2026 Biopharma Sentiment Index, 69% of respondents said the regulatory environment has deteriorated versus a year ago, with only 7% saying it improved. Many pointed to reviewer attrition, shifting expectations, and an "impossible to plan around" environment that keeps capital cautious even as deals begin to thaw.
FDA Commissioner Martin Makary and Vinay Prasad outlined their goal to move away from the long-standing norm of requiring two rigorous studies for many approvals toward one adequate and well-controlled study plus confirmatory evidence in certain cases. They acknowledge that advances in drug research have made overreliance on two trials unnecessary. This move represents a big potential shift for development strategy, timelines, and investment decisions, and could lead to significant cost savings and shorter timelines for biotechs.
FDA reversed course and agreed to review Moderna's application for its mRNA-based flu vaccine after it had announced that it had rejected its application for review a week prior. The sudden reversal is welcome but continues to highlight an uncertain regulatory environment for vaccine developers.
The future of ARPA-H's Investor Catalyst Hub in Cambridge is uncertain following a stop-work order and notice of intent to terminate the hub's agreement with VentureWell. ARPA-H has pushed back against reports of a full closure, stating it is evaluating vendors rather than closing the site. The hub has played a significant role in Massachusetts's innovation ecosystem, directing nearly $300 million in research funds to state organizations.
TrumpRx launched on February 5, 2026, as a new direct-to-consumer hub that routes cash-paying and uninsured patients to "most-favored-nation" style discount prices offered under agreements the Administration struck with large manufacturers including AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer. While about 40 brand-name medications are available on the site now, the Administration said more would be added soon. The early scrutiny centers on how much this helps insured patients and how the initiative functions as a parallel discount channel rather than a system-wide reform.
Senate HELP Chair Bill Cassidy released a report laying out legislative and regulatory proposals to "modernize" FDA, framing the goal as reducing unnecessary bottlenecks while sustaining U.S. biomedical leadership and getting patients timelier access to new treatments. Initial efforts include establishing clearer expectations and smoother pathways for novel trial approaches.